Radiology, Vol 192, 99-102, Copyright © 1994 by Radiological Society of North America

ARTICLES

Salivary gland tumors: pretherapy evaluation with PET

JW Keyes Jr, BA Harkness, KM Greven, DW Williams 3rd, NE Watson Jr and WF McGuirt
Department of Radiology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157.

PURPOSE: To determine whether positron emission tomography (PET) can help differentiate benign from malignant lesions of the salivary glands before surgery. MATERIALS AND METHODS: Masses of the salivary glands were examined in 26 patients by means of computed tomography, magnetic resonance imaging, PET, biopsy (n = 18), and surgery. Contiguous PET scans were obtained from the midcranium to the lower chest 45 minutes after administration of 370 MBq (10 mCi) of fluorine-18 fluorodeoxyglucose (FDG). Standard uptake values (SUVs) were determined for all suspect lesions and for normal parotid glands and cerebellum. RESULTS: All lesions were visualized, and all but two showed some increase in FDG uptake. PET findings helped correctly differentiate benign from malignant masses in 18 (69%) but were false-positive for malignancy in eight (31%). SUV analysis, lesion-to-normal SUV ratios, and lesion-to-cerebellar SUV ratios also failed to differentiate the lesions. CONCLUSION: FDG PET is not useful in classifying salivary gland tumors as benign or malignant.

This article has been cited by other articles:

				V. N. Shah and B. F. Branstetter IV Oncocytoma of the Parotid Gland: A Potential False-Positive Finding on 18F-FDG PET Am. J. Roentgenol., October 1, 2007; 189(4): W212 - W214. [Full Text] [PDF]

				H.-S. Jeong, M. K. Chung, Y.-I. Son, J. Y. Choi, H. J. Kim, Y. H. Ko, and C.-H. Baek Role of 18F-FDG PET/CT in Management of High-Grade Salivary Gland Malignancies J. Nucl. Med., August 1, 2007; 48(8): 1237 - 1244. [Abstract] [Full Text] [PDF]

				J.-L. Roh, C. H. Ryu, S.-H. Choi, J. S. Kim, J. H. Lee, K.-J. Cho, S. Y. Nam, and S. Y. Kim Clinical Utility of 18F-FDG PET for Patients with Salivary Gland Malignancies J. Nucl. Med., February 1, 2007; 48(2): 240 - 246. [Abstract] [Full Text] [PDF]

				T. M. Blodgett, M. B. Fukui, C. H. Snyderman, B. F. Branstetter IV, B. M. McCook, D. W. Townsend, and C. C. Meltzer Combined PET-CT in the Head and Neck: Part 1. Physiologic, Altered Physiologic, and Artifactual FDG Uptake RadioGraphics, July 1, 2005; 25(4): 897 - 912. [Abstract] [Full Text] [PDF]

				J.-H. Kim, J. Czernin, M. S. Allen-Auerbach, B. S. Halpern, B. J. Fueger, J. R. Hecht, O. Ratib, M. E. Phelps, and W. A. Weber Comparison Between 18F-FDG PET, In-Line PET/CT, and Software Fusion for Restaging of Recurrent Colorectal Cancer J. Nucl. Med., April 1, 2005; 46(4): 587 - 595. [Abstract] [Full Text] [PDF]

				G J R Cook Nuclear medicine in imaging head and neck malignancies Imaging, September 1, 2003; 15(3): 141 - 148. [Abstract] [Full Text] [PDF]

				D. M. Yousem, M. A. Kraut, and A. A. Chalian Major Salivary Gland Imaging Radiology, July 1, 2000; 216(1): 19 - 29. [Abstract] [Full Text]